Form 4: Edgewise Therapeutics CMO, Joanne M. Donovan, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Edgewise Therapeutics' Chief Medical Officer, Joanne M. Donovan, exercised stock options and sold 25,000 shares of common stock on January 28, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics, executed a stock option to acquire 25,000 shares of common stock at a price of $7.08 per share on January 28, 2025.
• On the same day, Ms. Donovan sold 25,000 shares of common stock at an average price of $27.6263 per share, with individual sales ranging from $27.09 to $27.96.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2024.
• Following these transactions, Ms. Donovan beneficially owns 16,358 shares of common stock directly and 175,000 stock options.
• The stock options vest monthly, with 1/48th of the shares vesting each month starting September 17, 2023, contingent on continued service.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction by a company officer under a pre-arranged plan. There is no indication of positive or negative sentiment, it is a neutral event.

Risks

• The sale of shares by a company officer could be perceived negatively by the market, although it was conducted under a pre-arranged trading plan.
• The vesting schedule of the stock options is contingent on continued service, which could be a risk if Ms. Donovan were to leave the company.

Industry Context

This is a routine transaction for a company officer, and the use of a 10b5-1 plan is a common practice to avoid accusations of insider trading. The stock option exercise and sale are part of the standard compensation and equity management practices for executives in publicly traded companies.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Amgen or Regeneron, to manage their stock transactions and avoid potential insider trading issues.
• The vesting schedule of the stock options, with monthly vesting over four years, is also a standard practice in the industry, similar to what is seen at companies like Gilead Sciences or Vertex Pharmaceuticals.
• The average sale price of $27.6263 per share is a specific data point for this transaction, and it would be compared to the current market price of Edgewise Therapeutics stock to assess the impact of the sale.

Stakeholder Impact

• The sale of shares by a company officer could have a minor impact on shareholder sentiment, but the pre-arranged nature of the transaction mitigates this risk.
• The stock option exercise and sale do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, insider trading, Rule 10b5-1, share sale, Edgewise Therapeutics, CMO, Joanne M. Donovan, equity